Iniparib data headlines Sanofi's ASCO portfolio

Sanofi (Euronext:SAN; NYSE:SNY) announced the availability of abstracts slated for presentation at the American Society of Clinical Oncology meeting, including an abstract for additional Phase III data of iniparib ( BSI-201) in metastatic triple-negative breast cancer. However, the data investors may be most looking for -- an analysis of a narrower population that may have performed better in the trial than the overall population -- won't be disclosed until the meeting, which starts June 3 in Chicago.

In January, Sanofi said iniparib plus gemcitabine and carboplatin missed the trial's co-primary endpoints of significantly improving overall survival and progression-free survival vs. chemotherapy alone. At that time, Sanofi said a pre-specified analysis of patients treated in the second- and third-line setting displayed OS and PFS improvements that were consistent with what was seen in a Phase II trial (see BioCentury, Jan. 27). ...